Trials / Completed
CompletedNCT00239291
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib, radiotherapy |
Timeline
- Start date
- 2003-01-01
- Completion
- 2006-05-01
- First posted
- 2005-10-17
- Last updated
- 2009-04-23
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00239291. Inclusion in this directory is not an endorsement.